CD274 and neoplasm: Indeed, PDL1 expression has been associated with clinical benefit across different tumor types [7], despite conflicting data that have been attributed to methodological issues (scoring system, antibodies, and platforms) and biological variability (transient expression, tumor heterogeneity) [7,19].